Clinical Trial: 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT03875209) titled '10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults' on Oct. 2, 2018.

Brief Summary: Many HIV-infected individuals mount a broad neutralizing serologic response 2-3 years after infection. Broadly neutralizing antibodies might play an important role in protection from acquisition of HIV infection because they can protect macaques from infection, and the presence of anti-HIV antibodies was the only positive correlate of protection in an HIV vaccine efficacy trial (RV144 trial). HIV neutralizing antibodies also have the potential to alter the course of HIV infection in humans. Therefore, these antibodies might be...